
Scoop: Roche-backed startup gives up on CD47, lays off all employees
Arch Oncology ended its work on developing an anti-CD47 antibody and most employees have left the company, Endpoints News has learned.
The Brisbane, CA, and St. Louis biotech scrapped clinical development of the antibody, dubbed AO-176, according to an automatic reply email from a former clinical operations director.
All Arch employees were let go and the company “was in a wind-down situation,” according to the LinkedIn bio of Arch’s former VP of human resources.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.